A Phase 1 Study of KT-333, a Targeted Protein Degrader of STAT3, in Patients with Relapsed or Refractory Lymphomas, Large Granular Lymphocytic Leukemia, and Solid Tumors

Authors: Smith, Stephen D ^*, Starodub, Alexander ^*, Stevens, Don A., Shastri, Aditi, Porcu, Pierluigi, Feldman, Tatyana, Ewesuedo, Reggie ^*, DeSavi, Chris ^*, Dey, Joyoti ^*, Agarwal, Sagar ^*, Donohue, Sean ^*, Perea, Rachelle ^*, Klaus, Christine ^*, Gollob, Jared ^*

Source: In Blood 15 November 2022 140 Supplement 1:12024-12025

A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers

Authors: Liu, Phillip CC, Dixit, Vaishali, Mayo, Michele, Dey, Joyoti, Yuan, Karen, Karnik, Rahul, Walther, Dirk, Shi, Yatao, Sharma, Kirti, Rong, Haojing, Yang, Bin, Gollerkeri, Ashwin, Gollob, Jared, DeSavi, Chris

Source: In Blood 23 November 2021 138 Supplement 1:1865-1865

Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens

Authors: Astone, Giuseppina, Cappelli, Luca Vincenzo, Chiu, William, Kayembe, Clarisse, Wang, Rui, Yang, Bin, Sharma, Kirti, Dey, Joyoti, Karnik, Rahul, Brambilla, Lara, Levy, David, Yoffe, Liron, Boccalatte, Francesco, Hernaez, Javier Rodriguez, Tsirigos, Aristotelis, Zumbo, Paul, Betel, Doron, Verma, Akanksha, Elemento, Olivier, Cumerlato, Michela, Piva, Roberto, Horwitz, Steven M., Epstein-Peterson, Zachary D., Gollob, Jared, DeSavi, Chris, Liu, Phillip CC, Inghirami, Giorgio

Source: In Blood 23 November 2021 138 Supplement 1:865-865

Mechanisms of the Anti-Tumor Activity of STAT3 Degraders in Lymphoma

Authors: Rong, Haojing ^*, Sharma, Kirti ^*, Csibi, Fred ^*, Yang, Bin ^*, Rusin, Scott ^*, Shi, Yatao ^*, Dey, Joyoti ^*, Karnik, Rahul ^*, Mayo, Michele ^*, Yuan, Karen ^*, Chutake, Yogesh ^*, McDonald, Alice ^*, Zhu, Sean ^*, Ji, Nan ^*, Liu, Phillip ^*, Li, Henry ^*, Walker, Duncan, Gollob, Jared ^*, Mainolfi, Nello ^*, Desavi, Chris ^*

Source: In Blood 5 November 2020 136 Supplement 1:42-42